Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penn Microbiome Therapy for Severe C. difficile Infection
NCT03970200Phase 2Terminated
- Sponsor
- University of Pennsylvania
- Start
- Jan 2020
- Primary completion
- Nov 2021
- Modality
- Cell Therapies, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Clostridioides difficile infection (CDI) (3 arms), sponsored by University of Pennsylvania. Primary endpoint: Number of Subjects With Resolution of Symptoms After Treatment With One of the PMT Suite of Products at 3 days. Started Jan 2020; status: terminated.
02
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT03970200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03970200.